Company / Operating Income per Share
Halozyme Operating Income per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
$3.81
FY2025
5-year range
-$0.50 / $4.35
FY2021-FY2025
Trend
-12.4%
vs FY2024
Sector context
#19 of 201
Health Care
What the data says
Among 201 Health Care companies, Halozyme is in the top 9% for operating income per share. Operating Income per Share has fluctuated over the past 10 years, ranging from $-0.51 in FY2020 to $4.35 in FY2024.
Based on SEC 10-K filings.
3.81 in FY2025 with a 3-year CAGR of +25.1%. Top quartile in the Health Care sector.
Improved from $2.50 to $3.81 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- +25.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
+217.8% above sector average
Key checks
Key Insights
- In FY2025, operating income per share decreased 12.4% year-over-year.
- Ranks #19 out of 201 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2024.
- Lowest operating income per share in the period was in FY2020.
Company context
Key Data Points
- Strong profit margin: 47.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 118.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.81 | -12.4% |
| FY2024 | $4.35 | +74.2% |
| FY2023 | $2.50 | +28.4% |
| FY2022 | $1.95 | +488.6% |
| FY2021 | -$0.50 | +1.3% |
| FY2020 | -$0.51 | -190.6% |
| FY2019 | $0.56 | +215.3% |
| FY2018 | -$0.49 | -177.6% |
| FY2017 | $0.63 | +227.2% |
| FY2016 | -$0.49 | +23.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026